Multiple, diffuse schwannomas in a RASopathy phenotype patient with germline KRAS mutation: A causal relationship?

Clinical Genetics

Volumn 81, Issue 6, 2012, Pages 595-597

  Bertola, D R ^a   Pereira, A C ^b   Brasil, A S ^a   Suzuki, L ^b   Leite, C ^b   Falzoni, R ^b   Tannuri, U ^b   Poplawski, A B ^c   Janowski, K M ^c   Kim, C A ^a   Messiaen, L M ^a  

^a Instituto da Criança   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANAMNESIS; CASE REPORT; GENE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KRAS GENE; LETTER; MALE; MULTIPLE DIFFUSE SCHWANNOMA; NEURILEMOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; PRIORITY JOURNAL;

CHILD; CHROMOSOMAL PROTEINS, NON-HISTONE; DNA-BINDING PROTEINS; FEMALE; GERM-LINE MUTATION; HUMANS; NEURILEMMOMA; NEUROFIBROMIN 2; PHENOTYPE; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TRANSCRIPTION FACTORS; YOUNG ADULT;

EID: 84860585300     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2011.01764.x     Document Type: Letter

References (26)

1. Kratz CP, Niemeyer CM, Zenker M. An unexpected new role of mutant Ras: perturbation of human embryonic development. J Mol Med 2007: 85: 227-235.
2. Huang JH, Simon SL, Nagpal S, Nelson PT, Zager EL. Management of patients with schwannomatosis: report of six cases and review of the literature. Surg Neurol 2004: 62: 353-361.
3. Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev 2009: 19: 230-236.
4. Tartaglia M, Zampino G, Gelb BD. Noonan syndrome: clinical aspects and molecular pathogenesis. Mol Syndromol 2010: 1: 2-26.
5. Kratz CP, Rapisuwon S, Reed H, Hasle H, Rosenberg PS. Cancer in Noonan, Costello, cardiofaciocutaneous and LEOPARD syndromes. Am J Med Genet C Semin Med Genet 2011: 157: 83-89.
6. Jongmans MC, van der Burgt I, Hoogerbrugge PM et al. Cancer risk in patients with Noonan syndrome carrying a PTPN11 mutation. Eur J Hum Genet 2011: 19: 870-874.
7. Gripp KW, Scott CI Jr, Nicholson L et al. Five additional Costello syndrome patients with rhabdomyosarcoma: proposal for a tumor screening protocol. Am J Med Genet 2002: 108: 80-87.
8. Gripp KW. Tumor predisposition in Costello syndrome. Am J Med Genet C Semin Med Genet 2005: 137C: 72-77.
9. Bertola DR, Pereira AC, Brasil AS, Albano LM, Kim CA, Krieger JE. Further evidence of genetic heterogeneity in Costello syndrome: involvement of the KRAS gene. J Hum Genet 2007: 52: 521-526.
10. Gonzalvo A, Fowler A, Cook RJ et al. Schwannomatosis, sporadic schwannomatosis, and familial schwannomatosis: a surgical series with long-term follow-up. J Neurosurg 2011: 114: 756-762.
11. Hadfield KD, Newman WG, Bowers NL et al. Molecular characterisation of SMARCB1 and NF2 in familial and sporadic schwannomatosis. J Med Genet 2008: 45: 332-339.
12. Sestini R, Bacci C, Provenzano A, Genuardi M, Papi L. Evidence of a four-hit mechanism involving SMARCB1 and NF2 in schwannomatosis-associated schwannomas. Hum Mutat 2008: 29: 227-231.
13. Kaplan MS, Opitz JM, Gosset FR. Noonan's syndrome. A case with elevated serum alkaline phosphatase levels and malignant schwannoma of the left forearm. Am J Dis Child 1968: 116: 359-366.
14. Suri M, Garrett C. Costello syndrome with acoustic neuroma and cataract. Is the Costello locus linked to neurofibromatosis type 2 on 22q? Clin Dysmorphol 1998: 7: 149-151.
15. Johannessen CM, Reczek EE, James MF, Brems H, Legius E, Cichowski K. The NF1 tumor suppressor critically regulates TSC2 and mTOR. Proc Natl Acad Sci U S A 2005: 102: 8573-8578.
16. Gremer L, Merbitz-Zahradnik T, Dvorsky R et al. Germline KRAS mutations cause aberrant biochemical and physical properties leading to developmental disorders. Curr Opin Genet Dev 2009: 19: 230-236.
17. Kratz CP, Zampino G, Kriek M et al. Craniosynostosis in patients with Noonan syndrome caused by germline KRAS mutations. Am J Med Genet A 2009: 149A: 1036-1040.
18. Hasle H. Malignant diseases in Noonan syndrome and related disorders. Horm Res 2009: 72 (Suppl. 2): 8-14.
19. Zenker M, Lehmann K, Schulz AL et al. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations. J Med Genet 2007: 44: 131-135.
20. Schubbert S, Zenker M, Rowe SL et al. Germline KRAS mutations cause Noonan syndrome. Nat Genet 2006: 38: 331-336.
21. Carta C, Pantaleoni F, Bocchinfuso G et al. Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet 2006: 79: 129-135.
22. Niihori T, Aoki Y, Narumi Y et al. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome. Nat Genet 2006: 38: 294-296.
23. Søvik O, Schubbert S, Houge G et al. De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardio-facio-cutaneous features. J Med Genet 2007: 44: e84.
24. Nyström AM, Ekvall S, Berglund E et al. Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders. J Med Genet 2008: 45: 500-506.
25. Lo FS, Lin JL, Kuo MT et al. Noonan syndrome caused by germline KRAS mutation in Taiwan: report of two patients and a review of the literature. Eur J Pediatr 2009: 168: 919-923.
26. Huang JH, Simon SL, Nagpal S, Nelson PT, Zager EL. Management of patients with schwannomatosis: report of six cases and review of the literature. Surg Neurol 2004: 62: 353-361.